<div id="readability-page-1"><div>Edesa Biotech, Inc., a biopharmaceutical company focused on acquiring, developing, and commercializing drugs for inflammatory and immune-related diseases, has released its Form 10-Q report for the third quarter. The report provides a comprehensive overview of the company's financial performance and operational advancements, underscoring its commitment to addressing unmet medical needs and exploring large market opportunities. Financial Highlights Net Loss: $2.2 million, reflecting an increase from the previous year's net loss of $1.6 million, primarily due to higher operating expenses.Loss per Common Share - Basic and Diluted: $0.28, compared to $0.48 for the same period last year, indicating a decrease in loss per share despite the increased net loss, likely due to a higher number of shares outstanding. Business Highlights Product Development - Medical Dermatology Edesa Biotech is advancing its EB06 monoclonal antibody candidate for vitiligo, with regulatory approval from Health Canada for a Phase 2 study and ongoing discussions with the FDA. The company plans to initiate enrollment by mid-2026. Product Development - Respiratory The company's most advanced candidate, EB05 (paridiprubart), showed significant results in a Phase 3 study for ARDS. It is also part of a U.S. government-funded study for ARDS and is being explored for chronic disease applications. Operational Strategy Edesa Biotech focuses on acquiring, developing, and commercializing drugs for inflammatory and immune-related diseases, prioritizing areas with unmet medical needs and large market opportunities. Future Outlook - Clinical Trials The company anticipates starting a Phase 2 study for EB06 in vitiligo patients by mid-2026, subject to regulatory approval, and is evaluating additional uses for EB05 in chronic diseases. Strategic Partnerships Edesa Biotech is leveraging government grants, such as the Canadian SRF, to support its clinical programs, including the development and potential commercialization of EB05. Regulatory Progress The company has received regulatory approval from Health Canada for a Phase 2 study of EB06 and is in discussions with the FDA for the same study, indicating progress in its regulatory strategy. Research and Development Focus Edesa Biotech's R&amp;D efforts are concentrated on advancing its clinical pipeline in Medical Dermatology and Respiratory, with a focus on EB06 for vitiligo and EB05 for ARDS. Operational Challenges The company acknowledges the need for additional funding to continue its operations and advance its clinical programs, highlighting the importance of strategic financing and partnerships.SEC Filing: Edesa Biotech, Inc. [ EDSA ] - 10-Q - Feb. 13, 2026</div></div>

IBBQ

EDSA

SBIO

Edesa Biotech, Inc. has released its Form 10-Q report for Q3, revealing a net loss of $2.2 million, up from $1.6 million last year. Loss per share decreased to $0.28 from $0.48, attributed to a higher number of shares. The company is advancing its EB06 monoclonal antibody for vitiligo, with a Phase 2 study expected to start by mid-2026, and EB05 for ARDS, showing significant Phase 3 results. Edesa is focusing on strategic partnerships and regulatory approvals to support its clinical programs, while acknowledging the need for additional funding to continue operations.

Edesa Biotech, Inc. SEC 10-Q Report